Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : CytoReason teams with Pfizer on drug discovery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:44am EST

The Israeli company will earn over $10 million for its machine learning cell-centered models of the immune system.

Israeli machine learning company CytoReason, which has developed cell-centered models of the immune system for drug discovery has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE). Pfizer will pay CytoReason amounts, "equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments."

The Tel Aviv-based company`s proprietary platform helps rebuild lost cellular information from gene expression data and associates genes to specific cells. This information is then integrated with additional omics and literature data to create a cell-based model of the trial-specific immune response. Integration with the CytoReason disease model empowers the study analytics and allows the model to learn and improve, leading to robust target discovery, drug response biomarkers and indication selection.

CytoReason CEO David Harel said, The collaboration with Pfizer will further strengthen our models in our core therapeutic areas. This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline. CytoReasons model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.

We believe that CytoReasons platform has the potential to offer valuable insights that may be applied to our research into the human immune system, said Michael Vincent, CSO, Inflammation & Immunology, Pfizer. Leveraging technologies such as this can help us understand disease and prioritize targets, and support our mission of bringing innovative new therapies to patients who need them.

CytoReason was represented by Adv Yael Baratz from Pearl Cohen Zedek Latzer Baratz law firm.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
01:15aPFIZER : GSK chairman Sir Philip Hampton to step down following Pfizer venture
AQ
01/21EXCLUSIVE : Private equity firms circling Nestle's skin health business - source..
RE
01/21GlaxoSmithKline Chairman Philip Hampton to Step Down -- Update
DJ
01/21PHILIP HAMPTON : GSK Chairman Hampton to step down ahead of split
RE
01/21GSK Chairman Hampton to step down ahead of split
RE
01/19PFIZER : cuts five biosimilar candidates and 150 jobs in R&D shakeup
AQ
01/19JOHNSON & JOHNSON : J&Js Erleada cleared for early prostate cancer in Europe
AQ
01/19PFIZER : inks collaboration deal to use CytoReason`s cell-centered models of imm..
AQ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/18PFIZER : Pakistan Limited and Pakistan Bait-ul-Mal, Government of Pakistan signs..
AQ
More news
Financials ($)
Sales 2018 53 608 M
EBIT 2018 20 023 M
Net income 2018 13 632 M
Debt 2018 28 504 M
Yield 2018 3,22%
P/E ratio 2018 18,04
P/E ratio 2019 17,13
EV / Sales 2018 5,13x
EV / Sales 2019 5,05x
Capitalization 247 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 45,3 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.57%246 674
JOHNSON & JOHNSON1.27%350 508
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291
AMGEN4.73%129 916